Correlation between the methylation status of C-erbB-2 gene promoter region CpG island and androgen receptor expression in breast cancer

doi:10.3969/j.issn.1673-8640.2018.06.018

Abstract

Abstract:

Objective To investigate the correlation between androgen receptor（AR） and the methylation status of human epidermal growth factor receptor（C-erbB-2） gene promoter region CpG island in breast cancer,and to study the relationship between AR and clinical prognosis. Methods A total of 76 patients with breast cancer and 55 patients with benign breast tumor were enrolled,and the methylation status of C-erbB-2 gene promoter region CpG island and the expression level of AR were determined by methylation-specific polymerase chain reaction（MSP） and immunohistochemistry（IHC）,respectively. Based on clinical and pathological data,the relationship between AR and the methylation status of C-erbB-2 gene promoter region CpG island was evaluated,and the prognosis analysis was performed. Results The methylation proportion of C-erbB-2 gene promoter region CpG island in AR positive breast cancer tissue [74.58%（44/59）] was higher than that in AR negative breast cancer tissue [47.06%（8/17）]（P=0.032）. The methylation of C-erbB-2 gene promoter region CpG island was positively correlated with AR expression（r=0.247,P=0.032）,and the tumor free survival rate of AR positive patients was higher than that of AR negative patients（P<0.05）. Conclusions The expression status of AR in breast cancer tissue can be used as one of prognosis predictors. The methylation of C-erbB-2 gene promoter region CpG island is positively related to the expression status of AR,which provides a new reference for hormone therapy and breast cancer prognosis.

Key words: Androgen receptor, Human epidermal growth factor receptor gene, Methylation, Breast cancer

CLC Number:

R446.62

YAN Peiyi, YUAN Ya, ZHANG Ji, ZHU Qi, ZOU Yuhan, WANG Gaoying, JIN Shu. Correlation between the methylation status of C-erbB-2 gene promoter region CpG island and androgen receptor expression in breast cancer[J]. Laboratory Medicine, 2018, 33(6): 549-555.

Figures/Tables 6

References 20

[1]	LEUNG E Y,ASKARIAN-AMIRI M E,SARKAR D,et al. Endocrine therapy of estroge receptor-positive breast cancer cells:early differential effects on stem cell markers[J]. Front Oncol,2017,7:184.
[2]	SCHRIJVER WAME,SCHUURMAN K,VAN ROSSUM A,et al.Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy[J]. Oncotarget,2017,8(33):55550-55561.
[3]	NAHLEH Z.Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer:an unchartered territory[J]. Future Oncol,2008,4(1):15-21.
[4]	HARDIN C,POMMIER R,CALHOUN K,et al.A new hormonal therapy for estrogen receptor-negative breast cancer[J]. World J Surg,2007,31(5):1041-1046.
[5]	SPEERS C,ZHAO S G,CHANDLER B,et al.Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer[J]. NPJ Breast Cancer,2017,3:29.
[6]	TONG Z J,SHI N Y,ZHANG Z J,et al. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis[J]. Biosci Rep,2017,37(4):pii:BSR20170121.
[7]	CALLAHAN C L,WANG Y,MARIAN C,et al.DNA methylation and breast tumor clinicopathological features:the Western NewYork Exposures and Breast Cancer(WEB) study[J]. Epigenetics,2016,11(9):643-652.
[8]	PARK S Y,KWON H J,CHOI Y,et al.Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes[J]. Mod Pathol,2012,25(2):185-196.
[9]	ZHAO L,NIU F,SHEN H,et al.Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer[J]. Virchows Arch,2016,468(6):687-696.
[10]	ESTELLER M,CORN P G,BAYLIN S B,et al.A gene hypermethylation profile of human cancer[J]. Cancer Res,2001,61(8):3225-3229.
[11]	MOASSER M M.The oncogene HER2:its signaling and transforming functions and its role in human cancer pathogenesis[J]. Oncogene,2007,26(45):6469-6487.
[12]	ELSTRODT F,HOLLESTELLE A,NAGEL J H,et al.BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants[J]. Cancer Res,2006,66(1):41-45.
[13]	SHIPPINGER W,REGITNIG P,DANDACHI N,et al.Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer[J]. Virchows Arch,2006,449(1):24-30.
[14]	BENEVOLENSKAYA E V,ISLAM A B,AHSAN H,et al.DNA methylation and hormone receptor status in breast cancer[J]. Clin Epigenetics,2016,8:17.
[15]	HODGSON M C,VANOSTRAN G,ALGHAMDI S,et al.Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice[J]. PLoS One,2013,8(4):e60455.
[16]	尼杰,沈立杰,霍俊杰,等. 雄激素受体在Her-2过表达型乳腺癌中的表达及其临床意义[J]. 实用医学杂志,2016,32(17):2854-2856.
[17]	SIMANAINEN U,GAO Y R,WALTERS K A,et al.Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors[J].Horm Cancer,2012,3(3):113-124.
[18]	金姝,朱琪,秦华晖,等. 乳腺癌C-erbB-2蛋白表达与基因CpG岛甲基化状态和mRNA表达的关系[J]. 检验医学,2011,26(11):750-755.
[19]	LOIBL S,MÜLLER B M,VON MINCKWITZ G,et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy[J]. Breast Cancer Res Treat,2011,130(2):477-487.
[20]	CASTELLANO I,ALLIA E,ACCORTANZO V,et al.Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers[J]. Breast Cancer Res Treat,2010,124(3): 607-617.

引物名称	序列（5'~3'）	产物大小（bp）
甲基化引物	MF AGGGAATTTATTTCGGATTTC	138
	MR CGCAAACCTAAATACGTCC
非甲基化引物	UF TTTAGGGAATTTATTTTGGATTTT	138
	UR CACAAACCTAAATACATCCCTC
野生型引物	WF GTGGACAGTCGAGACGCTCAG	440
	WR TGGTTGGGACAGGTTGCTAT

引物名称	序列（5'~3'）	产物大小（bp）
甲基化引物	MF AGGGAATTTATTTCGGATTTC	138
	MR CGCAAACCTAAATACGTCC
非甲基化引物	UF TTTAGGGAATTTATTTTGGATTTT	138
	UR CACAAACCTAAATACATCCCTC
野生型引物	WF GTGGACAGTCGAGACGCTCAG	440
	WR TGGTTGGGACAGGTTGCTAT

组别	例数	癌组织AR蛋白表达		χ²值	P值
组别	例数	阳性	阴性	χ²值	P值
C-erbB-2蛋白表达				1.376	0.241
阳性组	49	36	13
阴性组	27	23	4
C-erbB-2基因启动子区 CpG岛的甲基化				4.625	0.032
阳性组	52	44	8
阴性组	24	15	9
ER蛋白表达				2.250	0.134
阳性组	39	33	6
阴性组	37	26	11
PR蛋白表达				1.749	0.186
阳性组	33	28	5
阴性组	43	31	12
三阴性乳腺癌				0.406	0.524
三阴性乳腺癌组	8	5	3
非三阴性乳腺癌组	68	14	54
生存情况				1.605	0.205
存活组	67	54	13
死亡组	9	5	4
月经情况				0.350	0.554
绝经后组	61	46	15
绝经前组	15	13	2
癌灶浸润				1.217	0.569
导管内组	4	4	0
导管组	72	55	17

组别	例数	癌组织AR蛋白表达		χ²值	P值
组别	例数	阳性	阴性	χ²值	P值
C-erbB-2蛋白表达				1.376	0.241
阳性组	49	36	13
阴性组	27	23	4
C-erbB-2基因启动子区 CpG岛的甲基化				4.625	0.032
阳性组	52	44	8
阴性组	24	15	9
ER蛋白表达				2.250	0.134
阳性组	39	33	6
阴性组	37	26	11
PR蛋白表达				1.749	0.186
阳性组	33	28	5
阴性组	43	31	12
三阴性乳腺癌				0.406	0.524
三阴性乳腺癌组	8	5	3
非三阴性乳腺癌组	68	14	54
生存情况				1.605	0.205
存活组	67	54	13
死亡组	9	5	4
月经情况				0.350	0.554
绝经后组	61	46	15
绝经前组	15	13	2
癌灶浸润				1.217	0.569
导管内组	4	4	0
导管组	72	55	17

组别	例数	癌组织C-erbB-2 基因启动子区CpG岛的甲基化		χ²值	P值
组别	例数	甲基化	非甲基化	χ²值	P值
C-erbB-2蛋白表达				5.447	0.020
阳性组	49	29	20
阴性组	27	23	4
AR蛋白表达				4.625	0.032
阳性组	59	44	15
阴性组	17	8	9
ER蛋白表达				2.680	0.102
阳性组	39	30	9
阴性组	37	22	15
PR蛋白表达				0.501	0.479
阳性组	33	24	9
阴性组	43	28	15
生存情况				0.068	0.794
存活组	67	45	22
死亡组	9	7	2
月经情况				0.588	0.443
绝经前组	15	12	3
绝经后组	61	40	21
癌灶浸润				0.068	0.794
导管内组	4	2	2
导管组	72	50	22